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ABSTRACT 
Objective: To develop a simple and a cheap UV spectrophotometric method for the quantitative estimation of Dabigatran etexilate in capsules and 
validate as per ICH guidelines.  
Methods: The optimized method uses triethyl ammonium phosphate aqueous solution (pH 2.5) as a solvent for the estimation of assay of 
Dabigatran etexilate in capsules at a wavelength of 325 nm.  
Results: The developed method resulted in Dabigatran etexilate exhibiting linearity in the range 5-15μg/ml. The assay precision is exemplified by 
relative standard deviation of 1.07%. Percentage Mean recovery was found to be in the range of 98-102, during accuracy studies. Method was found 
to be robust with respect to wavelength and pH of the solvent.  
Conclusion: A simple and a cheap UV spectrophotometric method was developed and validated for the quantitative estimation of Dabigatran 
etexilate in capsules as per ICH guidelines and hence it can be used for routine analysis in various pharmaceutical industries.  
Keywords: UV, Dabigatran etexilate, Method development, Validation. 
 
INTRODUCTION 
Dabigatran etexilate (DE) is the oral pro drug of the active moiety 
Dabigatran. Dabigatran etexilate pro-drug was developed due to the 
limited oral availability of Dabigatran, and it is converted into 
Dabigatran (DAB) in vivo via esterases enzyme. The drug substance is 
the mesylate salt form of the pro drug, called Dabigatran etexilate 
mesylate (DEM) (fig. 1). The chemical name (IUPAC) of Dabigatran 
etexilate mesylate is ethyl-N-{[2-({[4-((E)-amino {[(hexyloxy) 
carbonyl] imino} methyl) phenyl] amino} methyl)-1-methyl-1H-benz 
imidazol-5-yl] carbonyl}-Npyridin-2-yl-β-alaninate methanesulfonate 
[1] corresponding to the molecular formula C35H45N7O8S. Dabigatran is 
an oral anticoagulant drug that acts as a direct thrombin (factor IIa) 
inhibitor. It was developed by the pharmaceutical company 
Boehringer Ingelheim. It is an anticoagulant medicine used for the 
prevention of clots and emboli after orthopedic surgery (hip or knee 
replacement) and to prevent stroke and other systemic emboli in 
people with non-valvular atrial fibrillation (AF), a commonly occurring 
abnormal heart rhythm [2].  
Few analytical methods are reported for the determination of 
Dabigatran etexilate by UV [3], LC/MS [4] and UPLC MS/MS [5] in 
bulk and/or plasma. While two stability indicating assay methods 
are cited in the literature using HPLC in bulk [1, 6] and two methods 
in formulations [7-8]. As there exists only one UV 
spectrophotometric assay method in capsule dosage form [3] using 
acetonitrile as solvent, an organic solvent which is costly, we here 
report a cheap and rapid UV spectrophotometric method using 
triethyl ammonium phosphate aqueous solution (pH 2.5) as solvent 
for the quantitative estimation of Dabigatran etexilate in capsules 
and validate the method as per ICH guidelines.  
 
Fig. 1: Structure of dabigatran etexilate mesylate 
MATERIALS AND METHODS 
Materials 
Instrument 
A double beam UV-visible spectrophotometer (Shimadzu, model 
1800) having two matched quartz cells with 1 cm light path and 
loaded with UV probe software (version 2.41) was used for 
recording of spectra and measuring absorbance. An electronic 
analytical weighing balance (0.1 mg sensitivity, Shimadzu AY 220), 
digital pH meter (DELUX model 101) and a sonicator (sonica, model 
2200 MH) were used in this study.  
Chemicals and reagents 
Analytically pure sample of Dabigatran etexilate with purities 
greater than 99% was obtained as gift sample from Chandra labs, 
Hyderabad, India and tablet formulation [PRADAXA] was procured 
from APOLLO pharmacy, Hyderabad, India with labelled claim of 
150 mg. Triethylamine and ortho phosphoric acid were obtained 
from SD Fine chemicals (Hyderabad, India).  
Method 
Solvent 
Solvent is prepared by adding 5 ml of triethylamine to 1000 ml of 
distilled water and later pH was adjusted to 2.5 using 30% v/v of 
ortho phosphoric acid in water.  
Selection of suitable detection wavelength 
Suitable wavelength for the total experiment was determined by 
recording UV spectrum in the range of 200-400 nm for Dabigatran 
etexilate and suitable wavelength selected was 325 nm (fig. 2). 
Preparation of stock and working standard solution 
10 mg of Dabigatran etexilate was accurately weighed and taken in 100 
ml clean and dry volumetric flask containing 80 ml of solvent and then 
the solution was made up to the mark using the solvent. This is 
considered as the standard stock solution (100µg/ml). 1 ml of the stock 
solution was pipette out and made up to 10 ml to get a concentration 
10µg/ml, treated as the working standard, 100% target concentration.  
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Preparation of stock and working sample solution 
Not less than 20 capsules were taken, emptied and test stock solution 
A of Dabigatran etexilate mesylate (750μg/ml) was prepared by 
transferring weight equivalent to 37.5 mg of Dabigatran etexilate 
mesylate to 40 ml of solvent which is sonicated and shaken 
intermittently for 8 min and later made up to 50 ml with solvent. This 
solution was filtered using 0.22micron syringe filter. From the above 
stock solution, A 1 ml was pipetted out and made up to 10 ml to get 
stock solution B (75μg/ml). From stock solution B, 1.33 ml was 
pipetted out and made up to 10 ml to get working sample solution 
concentration equivalent to 10µg/ml, 100% target concentration. 
 
 
Fig. 2: UV spectrum of standard 
 
RESULTS AND DISCUSSION 
Method development 
Various solvents were explored including water, Hydrochloric acid 
at 0.1N and 0.05N and sodium hydroxide at 0.1N and 0.05N. 
Dabigatran etexilate was found to be soluble and stable for 
minimum of 1 hour at room temperature using triethyl ammonium 
phosphate aqueous solution (pH 2.5) and hence this solvent was 
initiated for the determination of suitable detection wavelength and 
working concentration of standard. In order to test the applicability 
of the developed method to a commercial formulation, assay of 
PRADAXA capsules were studied at working concentration. Assay for 
working concentration of sample at 325 nm was in acceptance limits 
(95-105%) using the solvent via intermittent shaking and sonication 
method for 20 minutes. Hence the method is optimized. Fig. 3 
illustrates UV spectrum for the sample.  
Method validation 
Validation of the analytical method is the process that establishes by 
laboratory studies in which the performance characteristics of the 
method meet the requirements for the intended analytical 
application. UV spectrophotometric method developed was 
validated according to International Conference on Harmonization 
(ICH) guidelines [9] for validation of analytical procedures. The 
method was validated for the parameters like linearity, accuracy, 
system precision, intra-day precision, inter-day precision/ 
intermediate precision/ruggedness and robustness. 
Precision 
System precision 
Six replicate recording of absorbance at 325 nm of 100% working 
concentration standard solution showed % RSD (Relative Standard 
Deviation) less than 2, which indicates acceptable reproducibility 
and thereby the precision of the system. System precision results are 
tabulated in table 1. 
Method precision 
Method precision was determined by performing assay of sample 
under the tests of (i) repeatability (Intraday precision) and (ii) 
Intermediate precision (Inter day precision or ruggedness) 
performed during 2 consecutive days by two different analysts, at 
100 % working concentration. 
 
 
Fig. 3: UV spectrum of sample 
 
Table 1: System precision results 







 Average 0.351 
 SD 0.001 
 % RSD 0.284 
 
Repeatability (Intra day precision) 
Six consecutive recording of absorbance at 325 nm of 100% working 
concentration of the sample from the same homogeneous mixture 
showed % RSD less than 2 concerning % assay, which indicate that the 
method developed is method precise by the test of repeatability and 
hence can be understood that the method gives consistently 
reproducible results (table 2). % Assay was calculated by the standard 
formula using absorbance of the sample and standard, dilution factors 
for standard and sample, average weight of sample, label claim and 
potency.  
 
Table 2: Intraday precision results 
n % Assay 







S. D. 1.08 
% RSD 1.07 
 
Intermediate precision (Inter day precision/Ruggedness) 
Assay precision between two consecutive days performed by 
different analysts of the sample showed % RSD less than 2, which 
indicate the method developed is inter day precise/rugged (table 3). 
Linearity 
Different concentrations (5-15µg/ml) of Dabigatran etexilate 
standard were prepared by serial dilutions from the stock solution 
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100 µg/ml. Calibration curve (fig. 4) was constructed by plotting the 
concentration of drug versus absorbance at 325 nm. The results 
show an excellent correlation between absorbance and 
concentration of drug within the concentration range (5-15µg/ml) 
for the drug (table 4). The correlation coefficient was greater than 
0.995, which meet the method validation acceptance criteria and 
hence the method is said to be linear in the range of 5-15µg/ml. 
 
Table 3: Inter day precision/Ruggedness results 
n Analyst 1 Analyst 2 
1  100.41 100.40 
2 100.68 100.15 
3 100.14 102.43 
4 101.20 98.14 
5 99.05 102.30 
6 102.30 101.86 
Average 100.63 100.88 
SD 1.08 1.65 
% RSD 1.07 1.63 
 
Table 4: Calibration curve 
% Level Concentration (µg/ml)  Absorbance 
50 5.00 0.176 
75 7.50 0.251 
100 10.0 0.329 
125 12.5 0.412 








Fig. 4: Linearity graph of Dabigatran etexilate mesylate 
 
Accuracy 
Accuracy was determined by means of recovery experiments, by 
the determination of % mean recovery of sample by percentage 
method at three different levels (50-150%, viz 5, 10 and 
15μg/ml). 50 to 150% of the sample solutions were prepared as 
per the procedure given in the methods from the sample stock 
solution B (75μg/ml).  
At each level, three determinations were performed. Percent mean 
recovery was calculated as shown in table 5. The accepted limits of 
recovery are 98%-102% and all observed data are within the 
required range which indicates good recovery values and hence the 
accuracy of the method developed. 
 
Table 5: Accuracy studies 
% Level Absorbance % recovery Mean % recovery % RSD 
50 0.184 99.85   
50 0.185 100.42 101.05 1.22 
50 0.186 100.97     
100 0.371 100.41   
100 0.370 100.14 100.41 0.26 
100 0.372 100.68     
150 0.550 99.22   
150 0.560 101.02 100.18 0.89 
150 0.556 100.3    
 
Robustness 
The robustness of an analytical method is a measure of its capacity 
to remain unaffected by small but deliberate variations in method 
parameters and provides an indication of its reliability during 
normal usage. It is concluded that the method is robust as it is found 
that the % RSD is less than 2 for the drug concerning % assay 
despite deliberate variations done concerning pH±0.2 and detection 
wavelength±2 nm (table 6). Table 7 summarizes the validation 
parameters.
 
Table 6: Robustness studies 
Variation 
parameter 
Variation Sample absorbance Standard absorbance % assay % RSD 
pH 2.3 0.376  100.9  
(±0.2)  0.378 0.354 101.15 0.13 
  0.376  100.9  
 2.7 0.359  100.3  
  0.356 0.34 99.47 0.42 
  0.358  100.02  
Wave length 323 0.368  99.31  
(±0.2)  0.364 0.352 98.23 0.56 
  0.367  99.04  
 327 0.368  98.47  
  0.371 0.355 99.28 0.78 
  0.374  100.04  
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Table 7: Optical characteristics and validation parameters of Dabigatran etexilate 
Parameters Results 
Detection wavelength (nm) 325 
Beer’s Law limits (µg/ml) 5-15 
Regression equation (y = mx+c) y = 0.03028x+0.0256 
Correlation coefficient (r2) 0.998 
Slope (m) 0.0328 
Intercept (c) 0.0256 
% Relative Standard Deviation (% RSD) System precision 0.284 
(% RSD) Intra-day precision 1.07 
(% RSD) Inter-day precision ≤ 2 
Accuracy (% Mean Recovery)  
 50 % Level 101.05 
 100 % Level 100.41 
Robustness  
pH (±0.2) (% RSD) ≤ 2 
Wavelength (±2 nm) (% RSD) ≤ 2 
 
CONCLUSION 
A cheap and a rapid UV spectrophotometric method was developed 
and validated for the quantitative estimation of Dabigatran etexilate 
in capsules as per ICH guidelines. The developed method resulted in 
Dabigatran etexilate exhibiting linearity in the range 5-15μg/ml. The 
precision is exemplified by relative standard deviation of 1.07%. 
Percentage Mean recovery was found to be in the range of 98-102, 
during accuracy studies. Accordingly it is concluded that the 
developed UV spectrophotometric method is accurate, precise, 
linear and rugged and therefore the method can be used for routine 
analysis of Dabigatran etexilate in tablets in various pharmaceutical 
industries. 
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